Bulk Pharmaceutical API Sources for FILSPARI

Bulk Pharmaceutical API Sources for FILSPARI

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemShuttle		140580
DC Chemicals		DC8191
MedChemexpress MCE		HY-17621
AbaChemScene		CS-7947
Chemieliva Pharmaceutical Co., Ltd		PBCM0448658

Bulk Active Pharmaceutical Ingredient (API) Sources for: FILSPARI

Last updated: July 27, 2025

Introduction

Filspari, with the generic name ferric citrate or ferric citrate hydrate, is a crystalline salt primarily used for its iron-modulating properties. It serves as a phosphate binder for patients with chronic kidney disease (CKD) on dialysis, helping manage hyperphosphatemia and iron deficiency anemia. As an essential component in pharmaceutical formulations, the sourcing of high-quality bulk APIs is crucial to ensure product efficacy, safety, and regulatory compliance. This article provides a comprehensive overview of bulk API sources for Filspari, analyzing market dynamics, key manufacturers, and strategic considerations vital for pharmaceutical industry stakeholders.

Overview of Filspari's API: Ferric Citrate

Ferric citrate functions by binding dietary phosphate in the gastrointestinal tract, reducing serum phosphate levels. Additionally, it supplies bioavailable iron, addressing anemia in CKD patients. The API, ferric citrate, is produced through complex chemical synthesis and crystallization processes that demand high purity standards, typically >99%. The manufacturing process involves the reaction of ferric salts with citrate, followed by purification and quality control measures compliant with Good Manufacturing Practices (GMP).

Global API Manufacturing Landscape

The production of ferric citrate API is concentrated primarily in countries with established pharmaceutical manufacturing infrastructure, notably China, India, and Europe. China and India dominate due to their extensive chemical synthesis capacities and cost efficiencies, whereas Europe maintains high regulatory standards influencing API quality profiles.

Key API Manufacturers for Ferric Citrate (Filspari)

1. Major API Suppliers in China

   • Shandong Xinhua Pharmaceutical Co., Ltd.
     This leading manufacturer supplies ferric citrate globally, adhering to ISO certifications. The company boasts a vertically integrated process, controlling raw material sourcing, synthesis, and quality testing.

   • Zhejiang Medicine Co., Ltd.
     Recognized for their GMP-compliant facilities, Zhejiang Medicine’s facility ensures high purity ferric citrate APIs, catering mainly to North American and European markets.

2. Indian API Manufacturers

   • Biological E Limited
     This firm specializes in complex chemical APIs, including ferric citrate, with aggressive expansion into global markets under strict regulatory standards.

   • GSP Crop Science
     Known for cost-competitive production, GSP Crop Science maintains quality standards aligned with US and EU pharmaceutical regulations.

3. European and North American Suppliers

   • BASF SE
     While primarily a chemical intermediary supplier, BASF provides ferric citrate intermediates used in pharmaceutical-grade APIs, compliant with stringent European specifications.

   • Evonik Industries
     Engaged in specialty chemical manufacturing, Evonik supplies high-purity ferric citrate components for pharmaceutical formulation in Europe.

Supply Chain and Geographic Considerations

Choosing an API supplier involves evaluating multiple factors:

• Regulatory Compliance: Suppliers must meet GMP standards, with certifications from agencies such as the FDA, EMA, or WHO prequalification.

• Quality Assurance: Stringent batch-to-batch consistency, impurity profiling, and stability testing data are critical.

• Cost and Lead Times: Asian suppliers often offer cost advantages, but longer lead times and logistical complexities may influence procurement strategies.

• Intellectual Property and Licensing: Ensuring the API source holds necessary licenses or has licensed production rights for filspari-specific formulations.

Emerging Trends in API Sourcing

The increasing global emphasis on supply chain resilience has prompted pharmaceutical companies to diversify API sourcing. Strategic alliances and partnerships are forming with multiple suppliers to mitigate risks associated with geopolitical disruptions, regulatory changes, and raw material availability.

Additionally, the advent of contract manufacturing organizations (CMOs) specializing in iron salts enhances industry options. Notably, the Global API market for ferric citrate is projected to grow significantly owing to increasing CKD prevalence worldwide.

Regulatory and Quality Assurance Landscape

APIs for pharmaceutical applications like Filspari are subject to rigorous regulatory oversight. Suppliers must comply with current Good Manufacturing Practices (cGMP) outlined by agencies such as the FDA and EMA. Regulatory submissions often necessitate detailed dossiers on manufacturing processes, impurity profiles, stability data, and supply chain transparency.

The International Conference on Harmonisation (ICH) guidelines influence API quality standards, emphasizing impurity testing, residual solvents, and assay validation.

Strategic Considerations for Pharmaceutical Companies

In selecting bulk API sources for Filspari:

• Due Diligence: Conduct comprehensive audits of supplier facilities, quality control systems, and compliance history.

• Long-term Reliability: Establish relationships with multiple verified suppliers to ensure assured supply and leverage competitive pricing.

• Supply Chain Transparency: Prioritize transparency on raw material sourcing, shipping logistics, and contingency plans.

• Regulatory Alignment: Choose suppliers familiar with filing requirements in target markets, simplifying registration and approval processes.

Conclusion

The API sourcing landscape for Filspari hinges on balancing quality, cost, and supply chain robustness. Major producers in China and India dominate global supply, with European suppliers emphasizing regulatory adherence. Strategic partnerships, due diligence, and compliance with stringent quality standards remain pivotal to ensure reliable API procurement and uninterrupted production of Filspari. As the global demand for phosphate binders and anemia therapies increases, optimizing API sourcing strategies offers a competitive advantage and ensures sustained patient access.

---

Key Takeaways

• Market Leaders: China and India are primary sources for ferric citrate API, with European companies providing high-quality, regulation-compliant options.
• Quality & Compliance: GMP certification and adherence to international standards are non-negotiable for API suppliers for Filspari.
• Supply Chain Resilience: Diversification and strategic supplier relationships mitigate risks associated with geopolitical and logistical disruptions.
• Regulatory Navigation: Understanding and aligning with global regulatory frameworks streamline market entry and product approvals.
• Future Outlook: Growing CKD prevalence and demand for phosphate binders position ferric citrate API sourcing as a critical component of pharmaceutical supply chains.

---

FAQs

1. What are the primary raw materials required for producing ferric citrate API?

   • Ferric salts (such as ferric chloride or ferrous sulfate) and citric acid are the main raw materials used in synthesizing ferric citrate API, requiring high purity grades.

2. How do regulatory agencies influence API sourcing decisions?

   • Agencies like the FDA and EMA mandate strict quality and safety standards; suppliers must demonstrate GMP compliance and provide comprehensive documentation to facilitate approvals.

3. Are there sustainable or environmentally friendly sources for ferric citrate API?

   • Some manufacturers are adopting green chemistry principles, reducing waste and energy consumption. Suppliers with ISO 14001 certification or similar environmental standards are preferable.

4. What challenges do companies face when sourcing ferric citrate API from emerging markets?

   • Challenges include variability in quality assurance practices, logistical complexities, and regulatory oversight, necessitating rigorous supplier audits.

5. What future trends could impact the API sourcing landscape for Filspari?

   • Increasing regulatory requirements, global supply chain disruptions, and advancements in manufacturing technologies will shape sourcing strategies for ferric citrate APIs.

---

Sources
[1] Global Market Insights. “Ferric Citrate Market Analysis & Trends,” 2022.
[2] U.S. Food and Drug Administration. “Good Manufacturing Practice (GMP) Regulations,” 2023.
[3] European Medicines Agency. “Guidelines on Pharmaceutical Quality Systems,” 2021.
[4] Industry Reports. “API Manufacturing in China and India,” Pharmaceutical Technology, 2022.